Benoît Den Eynde
Chairman, Scientific Committee - Co-Founder
Immunology
iTherapeutics
Belgium
Biography
Prof. Benoît Van den Eynde is the Director of the LICR Brussels Branch since 2010. He is an internationally recognized expert in tumor immunology, a field that he contributed in the early nineties by identifying some of the very first tumor antigens, which are currently tested as targets in clinical trials of cancer vaccines. He also uncovered biological processes of more general significance, such as antisense transcription and translation of alternative open-reading frames and the startling discovery of peptide splicing by the proteasome. His group was also the first one to demonstrate that many tumors express the enzymes indoleamine dioxygenase or tryptophan dioxygenase, which suppress T lymphocyte activity by locally depleting tryptophan in the microenvironment. Benoît holds a medical doctor degree and a Ph.D. in immunology from UCL. He has authored more than 60 peer-reviewed publications and has received several awards during his career, including the 2007 GlaxoSmithKline Prize and the Joseph Maisin Prize in Biomedical Sciences.
Research Interest
Immunology
